ALX Oncology Holdings Inc.

NASDAQ:ALXO

Biotechnology

Healthcare
$0.97 -2.12%

-$0.03 today

Market cap
$134.14M
Beta
0.45
P/E (TTM)
-0.9
EPS (TTM)
-$1.64
52W Low $0.40High $2.66

Volume 0.56M

Average 1.07M

ALXO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

ALX Oncology Holdings Inc.NASDAQ: ALXO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $139.6M rose 214661.5% year over year, ahead of the +403.3% change in trailing-twelve-month financing cash flow. Sequentially, it rose 20489.2% from the prior quarter. Over 3 fiscal years it compounded at -66.8% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +214661.5% holds above the trailing-twelve-month pace of +403.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$139.6M+20489.2% QoQ
Last fiscal yearDec 2025
$362K-98.8% YoY
LTMMar 2026
$139.89M+403.3% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+214661.5%——
1 year-98.8%——
3-year CAGR-66.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
362K USD
Year-over-year change
-98.8%
4-year CAGR
-38.1%

Financing Cash Flow vs competitors

How ALXO compares with its peers on the latest reported figures

  • ALXO's LTM Mar 2026 financing cash flow of $139.89M is the 5th largest of the 8 companies compared; the peer median is $141.69M.
  • Its year-over-year change of +403.3% is the highest of 8, against a peer median of +37.9%.
  • Over three fiscal years its annual growth of -66.8% compares with a peer median of +12.9%.
ALXO Competitors Peer median
Financing Cash Flow for ALXO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$777.92M +55.7%+86.4%741.0%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$358.67M +263.5%+14.0%835.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$180.34M +37.9%+28.0%562.2%
ANNXAnnexon, Inc.LTM Mar 2026$141.69M +10.0%-4.0%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$139.89M +403.3%-66.8%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$57.73M +12.7%+11.7%25658.2%
NKTXNkarta, Inc.LTM Mar 2026$147K +180.8%-91.4%—
BCYCBicycle Therapeutics plcLTM Mar 2026$143.84K -100.0%—0.2%
Peer median (excluding ALXO) $141.69M+37.9%+12.9%741.0%

Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.46M)(123.48M)(160.81M)(134.85M)(101.7M)
Depreciation & Amortization51K342K836K872K706K
Deferred Income Tax00000
Stock-Based Compensation13.91M23.84M26.27M27.09M12.58M
Change in Working Capital(4.03M)9.85M8.3M(12.43M)336K
Accounts Receivables00000
Inventory00000
Accounts Payables3.29M4.51M458K(4.02M)421K
Other Working Capital(7.32M)5.34M7.84M(8.41M)(85K)
Other Non-Cash Items5.42M228K(4.97M)(2.6M)3.93M
Operating Cash Flow(68.1M)(89.22M)(130.36M)(121.91M)(84.14M)
Capital Expenditures(4.92M)(1.43M)(1.27M)(447K)(212K)
Acquisitions (Net)0233.99K000
Purchases of Investments0(376.79M)(246.63M)(107.41M)(51.59M)
Sales of Investments0142.8M292.56M194.11M134.39M
Other Investing Activities0(233.99K)000
Investing Cash Flow(4.92M)(235.42M)44.66M86.26M82.59M
Debt Repayment(281K)9.61M(388K)(827K)(1.36M)
Common Stock Issued2.75M903K58.89M31.64M1.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(655K)792K00
Financing Cash Flow2.47M9.86M59.29M30.82M362K
Effect of Forex Changes00000
Net Change in Cash(70.55M)(314.78M)(26.42M)(4.84M)(1.19M)
Free Cash Flow(73.02M)(90.65M)(131.64M)(122.36M)(84.35M)

ALX Oncology Holdings Inc.

NASDAQ:ALXO

Intrinsic Alpha fair value

Locked

Current Price

$0.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.